Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Down 7.2%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)’s stock price was down 7.2% during mid-day trading on Tuesday . The company traded as low as 1.42 and last traded at 1.42. Approximately 4,018,949 shares traded hands during trading, an increase of 8% from the average daily volume of 3,734,385 shares. The stock had previously closed at 1.53.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Oppenheimer reiterated an “outperform” rating and set a $1.50 target price (up from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. B. Riley raised their price objective on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a report on Tuesday, April 9th.

Perspective Therapeutics Price Performance

The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02.

Insiders Place Their Bets

In other Perspective Therapeutics news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average price of 0.95 per share, with a total value of 57,409,487.05. Following the transaction, the insider now directly owns 116,773,394 shares in the company, valued at approximately 110,934,724.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were acquired at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares in the company, valued at 110,934,724.30. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Markus Puhlmann bought 280,000 shares of the firm’s stock in a transaction dated Wednesday, January 24th. The shares were acquired at an average price of 0.50 per share, for a total transaction of 140,000.00. Following the completion of the transaction, the insider now directly owns 1,375,425 shares in the company, valued at approximately 687,712.50. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 60,758,439 shares of company stock valued at $57,576,503. Company insiders own 5.72% of the company’s stock.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after acquiring an additional 50,000 shares in the last quarter. Wealth Effects LLC purchased a new stake in Perspective Therapeutics during the third quarter valued at approximately $30,000. Charles Schwab Investment Management Inc. purchased a new stake in Perspective Therapeutics during the third quarter valued at approximately $32,000. Creative Planning purchased a new stake in Perspective Therapeutics during the third quarter valued at approximately $35,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Perspective Therapeutics in the third quarter worth $42,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.